Insights › Sectors
Pharmaceuticals News Today
3 headlines on Pharmaceuticals cleared our tape in the last 7 days with a measured price reaction attached. 1 of them moved the underlying at least 0.35% within fifteen minutes. The largest measured reaction was +0.57% on MRK at Aug 27, 09:31 ET.
Price action when the news broke
JNJ
At week 52, Eli Lilly (LLY) reported that Taltz and Zepbound have further enhanced the disease
MoveSurge publish 07:01:44 ET
MoveSurge publish
07:01:44 ET
267.95
267.50
267.02
266.57
267.53
06:57
07:01
07:26
07:01:44 ET
What moved — last 7 days
| Time | Ticker | Headline | 1 min | 15 min | Volume |
|---|---|---|---|---|---|
| Aug 31, 07:01 ET | JNJ | At week 52, Eli Lilly (LLY) reported that Taltz and Zepbound have further enhanced the disease activity of psoriasis or psoriatic arthritis compared to Week 36, during which statistically significant improvements over Taltz alone were noted in the TOGETHER-PsO and TOGETHER-PsA studies. | +0.00% | +0.21% | — |
| Aug 28, 17:05 ET | JNJ | FDA Approves Stelara for Pediatric Ulcerative Colitis | +0.00% | +0.21% | — |
| Aug 27, 09:31 ET | MRK | Moderna Borrows $2 Billion To Expand Oncology Business | +0.97% | +0.57% | — |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Times are New York ET.
Our analysis
BioNTech Q2 2026: A 60% Revenue Collapse the Stock Didn't React To
BioNTech reported second-quarter 2026 results on August 4, 2026.
Why Is BioNTech Stock Barely Moving Today?
BioNTech's revenue fell roughly 60% and guidance was cut — but the stock didn't budge, because the market stopped valuing it on COVID vaccine sales a …